Who is sponsoring NCT02077777?

NCT02077777 is sponsored by SOFAR S.p.A..

What condition does NCT02077777 study?

NCT02077777 studies Colorectal Cancer.

What is the status of NCT02077777?

NCT02077777 is currently COMPLETED.

Last reviewed 2016-12-01 · How we verify

Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari "in Vivo" Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)

NCT02077777 Phase 2 COMPLETED

The purpose of this study is to obtain an "in vivo" confirmation that mesalazine induces the gene expression of μ-protocadherin and other related genes in the colon mucosa, as demonstrated in some "in vitro" experiments. .

Details

Lead sponsor	SOFAR S.p.A.
Phase	Phase 2
Status	COMPLETED
Enrolment	21
Start date	2012-10
Completion	2016-06

Conditions

Colorectal Cancer

Interventions

Mesalazine

Primary outcomes

Molecular analysis of gene expression levels of μ-protocadherin and other related proteins — 3 months
Molecular analysis (quantitative RT-PCR) of gene expression levels of μ-protocadherin, protocadherin 19, protocadherin 24, cadherin E, TCF7L2, TCF4, c-myc, Cyclin D1, p21waf1, VEGF, CD44, Met, KLF4 e CEBP-α and comparison of the levels assessed at the end of the treatment period with the baseline.

Countries

Italy